Skip to main content

Table 1 Baseline clinical characteristics and outcomes of primary retinal detachments by tamponade agent

From: Unexplained visual loss in retinal detachment repair: comparing gas, silicone oil and heavy silicone oil by multivariable regression.

 

Total

SF6

C2F6

C3F8

Densiron

SO 1000cs

SO 5000 cs

p Value

Total

1012

341

338

239

33

43

18

–

Age (years, IQR)

59 (53 to 68)

59 (53 to 67)

61 (54 to 67)

59 (52 to 66)

61 (55 to 74)

63 (54 to 71)

55 (37 to 63)

0.087

Gender (% Male)

648 (64.0%)

215 (63.0%)

204 (60.4%)

158 (66.1%)

26 (78.8%)

29 (67.4%)

16 (88.9%)

0.057

Laterality (% Right)

528 (52.2%)

172 (50.4%)

195 (57.7%)

113 (47.3%)

17 (51.5%)

21 (48.8%)

10 (55.6%)

0.213

High Myope (% Yes)

61 (6.0%)

20 (5.9%)

25 (7.4%)

10 (4.2%)

3 (9.1%)

2 (4.7%)

1 (5.6%)

0.659

Ocular Co-morbidities

212 (20.9%)

50 (14.7%)

73 (21.6%)

49 (20.5%)

18 (54.5%)

14 (32.6%)

8 (44.4%)

< 0.001

Preoperative Lens

       

–

Phakic

644 (69.0%)

241 (75.5%)

220 (69.0%)

138 (63.6%)

18 (60.0%)

17 (53.1%)

10 (62.5%)

0.012

Pseudophakic

289 (31.0%)

78 (24.5%)

99 (31.0%)

79 (36.4%)

12 (40.0%)

15 (46.9%)

6 (37.5%)

Macula Status

        

Off

497 (49.1%)

116 (34.0%)

192 (56.8%)

122 (51.0%)

23 (69.7%)

32 (74.4%)

12 (66.7%)

< 0.001

On

515 (50.9%)

225 (66.0%)

146 (43.2%)

117 (49.0%)

10 (30.3%)

11 (25.6%)

6 (33.3%)

Giant Retinal Tear

7 (0.7%)

0 (0.0%)

1 (0.3%)

0 (0.0%)

0 (0.0%)

3 (7.0%)

3 (16.7%)

< 0.001

PVR C

16 (1.6%)

0 (0.0%)

0 (0.0%)

3 (1.3%)

3 (9.1%)

8 (18.6%)

2 (11.1%)

< 0.001

Retinectomy

3 (0.3%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

3 (7.0%)

0 (0.0%)

< 0.001

Perfluorocarbon

36 (3.6%)

5 (1.5%)

5 (1.5%)

6 (2.5%)

3 (9.1%)

10 (23.3%)

7 (38.9%)

< 0.001

Combined Buckle/PPV

13 (1.3%)

1 (0.3%)

1 (0.3%)

6 (2.5%)

0 (0.0%)

4 (9.3%)

1 (5.6%)

< 0.001

Presentation to Surgery (days)

1 (0 to 4)

1 (0 to 1)

1 (0 to 4)

1 (0 to 5)

2 (0 to 7)

2 (0 to 7)

2 (0 to 7)

< 0.001

Postoperative Lens

       

–

Phakic

471 (46.5%)

187 (54.8%)

168 (49.7%)

107 (44.8%)

3 (9.1%)

3 (7.0%)

3 (16.7%)

< 0.001

Pseudophakic

541 (53.5%)

154 (45.2%)

170 (50.3%)

132 (55.2%)

30 (90.9%)

40 (93.0%)

15 (83.3%)

Duration of oil (days)

147 (91 to 215)

–

–

–

84 (68 to 124)

171 (125 to 222)

202 (162 to 308)

< 0.001

Visual Loss

57 (5.6%)

13 (3.8%)

14 (4.1%)

15 (6.3%)

2 (6.1%)

9 (20.9%)

4 (22.2%)

< 0.001

Unexplained Visual Loss

15 (1.5%)

1 (0.3%)

4 (1.2%)

2 (0.8%)

0 (0.0%)

5 (11.6%)

3 (16.7%)

< 0.001

  1. Age and days from review to operation days are reported as median (interquartile range) and Kruskal Wallis test used to compare continuous variables
  2. Chi Squared test to compare more than two nominal groups
  3. Statistical significance in bold
  4. GRT:Giant Retinal Tear, PVR:Proliferative Vitreoretinopathy